Therefore, regulation of these two major factors, RUNX2 and HIF-1α, may help overcome chemotherapeutic resistance, enhance overall and disease-free survival in patients with osteosarcoma, and stand out as an effective therapeutic approach. This evidence concerns the gene HIF1A and osteosarcoma.